Sign in
Not yet recruitingPhase 2

Cosmos Trial: Cerebroprotection Of AST-004 in Mild Complicated Traumatic Brain Injuries

Key facts

Who runs it
Astrocyte Pharmaceuticals Inc.
Where
Netherlands1 site in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 2
People taking part
48 people, planned
Started
11 May 2026
Expected to end
1 Jun 2028
Type of study
Interventional
Record updated
19 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Adult - age 18-70 years
  • Complicated-mild TBI - defined as Glasgow Coma Scale (GCS) 13-15 with traumatic lesions on head CT scan obtained in the ED
  • Subject has minor or no extracranial injuries
  • Injuries do not require admission to an intensive care unit
  • Able to initiate treatment with AST-004 within 12h from injury
  • Male and female participants of childbearing potential must agree to use an effective method of birth control or abstain from sexual relations that could result in pregnancy for 14 days after receiving treatment with AST-004
  • Informed Consent obtained from patient or a legally authorized representative (LAR)

Who cannot take part

  • Current abuse of any drugs that are illegal under the Dutch country law
  • Administration within the past 90 d of darolutamide, eltrombopag, febuxostat, fostamatinib, teriflunomide or need to administer these medications during the first 48 hours post-dose
  • Subject is under the influence of alcohol, any stimulant, nitrates, mind alternating illicit drug or of alternative medications or supplements with stimulant properties (e.g., ephedra) or vasodilatory properties (e.g., nitrate containing supplements) and in the opinion of the Investigator alters ability to complete study assessments and/or study results
  • Prior TBI within the previous 6 months
  • Patients who require acute surgical and/or neurosurgical interventions or sedation requiring endotracheal intubation
  • Known end-stage renal disease or receiving dialysis of any form
  • Participant has a pre-injury cognitive impairment that prevents them from completing clinical assessments as required
  • Known history of seizures including febrile seizures or a first degree relative with epilepsy
  • Subject has a major neurological (e.g., a history of a brain tumor, neurosurgery, stroke or transient ischemic attack (TIA), etc.) or psychiatric/behavioral disorder co-morbidity
  • Current enrollment in another interventional, therapeutic clinical study that may affect the results of this study (an observational study is acceptable)
  • Administration of, or plans for, a blood transfusion during study participation
  • Non-Dutch or English speaking ability or illiteracy that would interfere with understanding follow-up questionnaires
  • Time of injury cannot be determined
  • Females breastfeeding/lactating or with a positive pregnancy test
  • Venipuncture not feasible

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study will evaluate the safety and efficacy of AST-004 as a cerebroprotective treatment for patients with complicated mild TBI.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
19 October 2026